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Background and Purpose  The recently developed total cerebral small-vessel disease 
(CSVD) score might appropriately reflect the total burden or severity of CSVD. We investi-
gated whether the total CSVD score is associated with long-term outcomes during follow-up 
in patients with acute ischemic stroke.
Methods  In total, 1,096 consecutive patients with acute ischemic stroke who underwent 
brain magnetic resonance imaging were enrolled. We calculated the total CSVD score for 
each patient after determining the burden of cerebral microbleeds (CMBs), high-grade 
white-matter hyperintensities (HWHs), high-grade perivascular spaces (HPVSs), and as-
ymptomatic lacunar infarctions (ALIs). We recorded the date and cause of death for all of the 
patients using data from the Korean National Statistical Office. We compared the long-term 
mortality rate with the total CSVD score using Cox proportional-hazards models.
Results  CMBs were found in 26.8% of the subjects (294/1,096), HWHs in 16.4% 
(180/1,096), HPVSs in 19.3% (211/1,096), and ALIs in 38.0% (416/1,096). After adjusting for 
age, sex, and variables that were significant at p<0.1 in the univariate analysis, the total CSVD 
score was independently associated with long-term death from all causes [hazard ratio 
(HR)=1.18 per point, 95% confidence interval (CI)=1.07–1.30], ischemic stroke (HR=1.20 
per point, 95% CI=1.01–1.42), and hemorrhagic stroke (HR=2.05 per point, 95% CI=1.30–
3.22), but not with fatal cardiovascular events (HR=1.17 per point, 95% CI=0.82–1.67).
Conclusions  The total CSVD score is a potential imaging biomarker for predicting mortal-
ity during follow-up in patients with acute ischemic stroke.
Key Words   cerebral small-vessel diseases, cerebral microbleeds, white-matter hyperintensities, 
perivascular spaces, asymptomatic lacunar infarctions.
Total Cerebral Small-Vessel Disease Score is Associated with 
Mortality during Follow-Up after Acute Ischemic Stroke
INTRODUCTION
Cerebral small-vessel diseases (CSVDs) are defined as those involving a small perforating 
arteriole, which presents as cerebral microbleeds (CMBs), high-grade white-matter hyper-
intensities (HWHs), perivascular spaces (PVSs), and asymptomatic lacunar infarctions 
(ALIs) in brain magnetic resonance imaging (MRI).1 Although each CSVD can have a dif-
ferent impact on the clinical presentation, these individual types of CSVD have common 
risk factors or share similar mechanisms.2,3 Furthermore, they are also considered to be 
closely related to the risks of cognitive impairment, recurrent stroke, and growth of cerebral 
infarction at an early stage.1,4,5 Therefore, for predicting the prognosis after stroke, it may 
be reasonable to consider the various CSVDs as a single entity rather than separately.
A new scoring system called the total CSVD score has been proposed for capturing the 
overall effect of CSVD on the brain, rather than estimating only one or two individual CS-
VDs separately.6 This score has been linked with risk factors for CSVD and with cognitive 
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dysfunction in lacunar stroke patients,6,7 and it might be help-
ful for the rapid quantification or stratification of CSVD.6 More-
over, because the scoring system represents the overall CSVD 
burden, which may influence the short- and long-term out-
comes, it is possible that the total CSVD score is indicative 
of the mortality likelihood during follow-up after an acute 
stroke. However, no data supporting this have been reported 
previously.
We investigated whether the total CSVD score is associat-
ed with mortality during follow-up in patients with ischemic 
stroke.
METHODS
Study population
This study performed a retrospective analysis of prospective-
ly collected data. Between January 2009 and December 2010, 
1,215 consecutive patients with acute cerebral infarction or 
transient ischemic attack were admitted to our stroke cen-
ter within 7 days after symptom onset.8 All of the patients 
were thoroughly evaluated during their hospitalization, and 
their demographic data, medical history, clinical manifesta-
tions, and vascular risk factors were recorded. According to 
the standard protocol of our stroke center, all patients under-
went brain computed tomography (CT) and/or MRI, vascu-
lar imaging studies (digital subtraction angiography, mag-
netic resonance angiography, or CT angiography), chest 
radiography, 12-lead electrocardiography, and routine blood 
tests. Echocardiography was also performed as a standard 
evaluation. Most of the patients were admitted to the stroke 
unit and were kept under continuous electrocardiographic 
monitoring during their stay (average length=4.9 days).8,9 
We excluded 45 of the 1,215 patients who did not under-
go brain MRI due to the patient’s refusal, claustrophobia, or 
presence of metallic material in the body, 23 with no avail-
able gradient recalled echo (GRE) images, 20 with poor im-
age quality, and 6 with no vessel imaging data. Patients with 
stroke due to other determined etiology (n=25) were also 
excluded. These exclusions resulted in 1,096 patients finally 
being included in this study (Fig. 1). 
The Institutional Review Board of Severance Hospital, Yon-
sei University Health System approved this study and waived 
the need for informed consent from the patients due to the 
its retrospective and observational design. 
Brain MRI protocol and definition of CSVD
All MRI examinations were performed using a 3.0T MRI 
system (Achieva 3.0T, Philips Medical Systems, Best, the 
Netherlands; or MAGNETOM Trio 3.0T, Siemens, Amberg, 
Germany). MRI images were obtained parallel to the orbi-
tomeatal line using the following parameters: time repeti-
tion (TR)/time echo (TE)=2,600–6,500/42–70 ms, interslice 
gap=2 mm, field of view (FOV)=230×230 mm, slice thick-
ness=5 mm, six different directions of diffusion gradient (x, 
y, z, xy, yz, and zx), and two b values (0 and 1000) for diffu-
sion-weighted imaging (DWI); TR/TE=9,000/120 ms, 
FOV=230×230 mm, pixel spacing=0.449 mm/0.449 mm, 
and slice thickness=5 mm for fluid-attenuated inversion re-
covery (FLAIR) imaging; TR/TE=9,000/100 ms, FOV= 
230×230 mm, pixel spacing=0.240 mm/0.240 mm, and slice 
thickness=5 mm for T2-weighted images; and TR/TE=600/ 
16 ms, FOV=250×250 mm, pixel spacing=0.449 mm/0.449 
mm, and slice thickness=5 mm for GRE imaging.10,11 
CMBs manifested as punctate hypointense lesions smaller 
than 10 mm on GRE images.10 The extent of white-matter 
hyperintensities was determined on the FLAIR images for 
the periventricular white matter or deep white matter ac-
cording to the Fazekas scoring system.12 A Fazekas score of 
3 in periventricular white matter or ≥2 in deep white matter 
was considered to indicate HWHs. PVSs were defined as 
punctate and/or linear hyperintense lesions smaller than 3 
mm on T2-weighted images in the basal ganglia.13 PVSs of 
grade 2–4 in the basal ganglia were defined as high-grade 
perivascular spaces (HPVSs), based on a previous report.3 
ALIs were defined as a round or ovoid, subcortical, fluid-
filled cavity (signal similar to cerebrospinal fluid) of hyper-
All ischemic stroke or TIA patients admitted  
between January 2009 and December 2010 (n=1,215)
Finally, 1,096 patients enrolled
Brain MRI not performed
(n=45)
GRE not performed
(n=23)
Poor image quality
(n=20)
Vascular imaging not performed
(n=6)
Stroke of other determined etiology
(n=25)
Fig. 1. Selection of patients. GRE: gradient recalled echo, TIA: tran-
sient ischemic attack.
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intense lesions ≥3 mm and <15 mm in size on T2-weighted 
images with low signal intensity on T1-weighted images, 
with no relevant history of symptoms or signs. The existence 
of CMBs, HWHs, HPVSs, and ALIs was determined outside 
the acute infarct area (based on DWI), and these lesions were 
independently investigated by two neurologists (T.J.S. and 
J.K.) who were blinded to the patient’s clinical information. 
The total CSVD score was calculated for each patient on 
an ordinal scale from 0 to 4 by counting the presence of each 
of the four MRI features of CSVD, with a score of 1 point ap-
plied for the presence of each of CMB, HWH, HPVS, and 
ALI.6 The interobserver agreement values for the presence 
of CMBs, HWHs, HPVSs, and ALIs were 0.912, 0.956, 0.938, 
and 0.888, respectively (all p<0.05). Any disagreement about 
the presence of CSVD was resolved by consensus. 
Clinical and laboratory variables
We collected the patient’s data for traditional vascular risk 
factors14 and the previous stroke. Hypertension was defined 
as being present when a patient had been taking blood-pres-
sure-lowering agents or had a resting systolic blood pressure 
of ≥140 mm Hg or a diastolic blood pressure of ≥90 mm 
Hg in repeated measurements. Diabetes mellitus was diag-
nosed for a fasting blood glucose level of ≥7.0 mmol/L or 
treatment with oral glucose-lowering medications or insulin. 
Hyperlipidemia was diagnosed for a total cholesterol level 
of ≥6.2 mmol/L, a low-density lipoprotein cholesterol level 
of ≥4.1 mmol/L, or if the patient had taken lipid-lowering 
medications after a diagnosis of hyperlipidemia at admis-
sion. Patients were defined as smokers if they were current 
smokers or had stopped smoking within 1 year before the 
index stroke. Previous stroke was defined as having a previ-
ous stroke-like symptom combined with the presence of an 
ischemic lesion confirmed by brain imaging. A history of a 
transient ischemic attack was not included as a previous 
stroke. We further collected data relating to the patient’s pri-
or medication, coronary artery disease (a history of myocar-
dial infarction, unstable angina, or angiographically con-
firmed occlusive disease of the coronary artery), metabolic 
syndrome, and the thrombolytic or endovascular reperfusion 
therapy used for the index stroke. 
We also measured the white blood cell count, hemoglobin, 
hematocrit, and estimated glomerular filtration rate (eGFR) 
at admission. eGFR was calculated using the Modification 
of Diet in Renal Disease formula as eGFR=186.3×(serum 
creatinine-1.154)×(age-0.203)×(0.742 for women). All laboratory 
data were collected at admission.
Stroke severity was determined at admission using the 
National Institutes of Health Stroke Scale (NIHSS).15 The 
stroke classification was determined based on the Trial of Org 
10172 in Acute Stroke Treatment classification system.16 
Outcome measures 
We recorded the date and cause of death for each patient us-
ing data from the Korean National Statistical Office, which 
are based on death certificates and are known to be reliable.17 
The causes of death were classified according to the Inter-
national Classification of Disease (10th revision) and cate-
gorized into fatal cardiovascular events (I21–I25, R96, I49, 
and I50), fatal ischemic stroke (I63 or I69.3), or fatal hemor-
rhagic stroke (I60–I62). The censoring date was set as De-
cember 31, 2013. 
Statistical analyses
Statistical analyses were performed using the Windows SPSS 
software package (version 20.0, IBM Corporation, Armonk, 
NY, USA). The independent-samples t-test, Mann-Whitney 
U test, or Kruskal-Wallis test was used to compare continu-
ous variables, and Fisher’s exact test or the chi-square test 
was used to compare categorical variables, as appropriate. 
The association between the total CSVD score and mortali-
ty rate was analyzed using the Kaplan-Meier product-limit 
method with a log-rank test and multivariate Cox propor-
tional-hazards regression. A probability value of p>0.05 was 
considered statistically significant.
RESULTS
Comparisons of baseline characteristics according 
to CSVD burden
The baseline characteristics of the study population (n= 
1,096) are presented in Table 1. The patients were aged 66.3± 
11.8 years (mean±SD) and 61.5% (n=675) of them were male. 
In terms of stroke classification, cardioembolism (26.0%) 
was most common, followed by negative evaluation (24.7%), 
two or more causes identified (20.0%), large-artery athero-
sclerosis (18.8%), and lacune (10.5%). 
CMBs were found in 26.8% of the subjects (294/1,096), 
HWHs in 16.4% (180/1,096), HPVSs in 19.3% (211/1,096), 
and ALIs in 38.0% (416/1,096). Age, hypertension, previous 
stroke, and prior antiplatelet use were associated with the 
presence of any type of CSVD (Table 2). Patients with ALIs 
showed a lower initial stroke severity and more frequent la-
cunar stroke compared to those without ALIs (Table 2).
Five hundred and fifty patients (50.2%) had a total CSVD 
score of 0. ALIs were most commonly observed (67.5%) in 
the 252 patients with a score of 1. The most common combi-
nations were CMBs+ALIs, in the 107 patients (32.7%) with 
a score of 2, and CMB+HPVSs+ALIs, in the 113 patients 
(51.3%) with a score of 3. Seventy-four patients (6.8%) had 
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all four types of CSVD. A higher total CSVD score was asso-
ciated with advanced age, hypertension, previous stroke, not 
smoking, coronary artery disease, prior antiplatelet use, and 
decreased eGFR, while initial stroke severity and stroke mech-
anism did not vary with the total CSVD score (Table 1). 
Association between CSVD and mortality during 
follow-up
Among the total of 1,096 patients, 240 (21.9%) died at a me-
dian follow-up of 3.8 years (interquartile range=3.2–4.3 
years); 77 (32.1%) patients died of fatal ischemic stroke, 17 
(7.1%) of fatal cardiovascular events, and 9 (3.8%) of fatal 
hemorrhagic stroke. Among the other causes of death, malig-
nancy was the most common, followed by renal failure and 
diabetes mellitus (Supplementary Table 1 in the online-only 
Data Supplement). The Kaplan-Meier curve showed that all 
prespecified outcomes (all-cause mortality, fatal ischemic 
stroke, and fatal hemorrhagic stroke) other than fatal cardio-
vascular events were associated with the CSVD score (Fig. 2). 
In multivariate Cox regression analyses adjusting for age, 
sex, and variables that were significant at p<0.1 in the uni-
variate analysis, the presence of CMBs, HWHs, or HPVSs 
was independently associated with all-cause mortality (Table 
3). Fatal ischemic stroke was related to HWHs or HPVSs, 
while CMBs were associated with fatal hemorrhagic stroke 
during the long-term follow-up (Table 3). In addition, the 
total CSVD score (especially one of 4) was an independent 
predictor for all-cause mortality [hazard ratio (HR)=2.11, 
95% confidence interval (CI)=1.36–3.25], fatal ischemic 
stroke (HR=2.74, 95% CI=1.34–5.60), and fatal hemorrhagic 
stroke (HR=17.44, 95% CI=3.19–95.3), but not for fatal car-
diovascular events (HR=1.92, 95% CI=0.31–11.79) (Table 3). 
The long-term prognosis according to the initial stroke 
severity was investigated by dividing the study population 
into three groups: mild (NIHSS score=0–4), moderate (NI-
HSS score=5–15), and severe (NIHSS score>15). There was 
Table 1. Baseline characteristics by total SVD scores
SVD score Total (n=1,096) 0 (n=550) 1 (n=252) 2 (n=107) 3 (n=113) 4 (n=74) p value
Demographic data
Sex, male 675 (61.5) 341 (62.0) 164 (65.1) 57 (53.3) 68 (60.2) 44 (59.5) 0.320
Age, years 66.3±11.8 63.3±12.2 67.0±10.5 71.4±10.8 69.6±10.6 73.1±10.0 <0.001
Risk factors
Hypertension 828 (75.5) 363 (66.0) 198 (78.6) 95 (88.8) 104 (92.0) 68 (91.9) <0.001
Diabetes mellitus 341 (31.1) 149 (27.1) 90 (35.7) 36 (33.6) 41 (36.3) 25 (33.8) 0.071
Hyperlipidemia 116 (10.6) 63 (11.5) 25 (9.9) 4 (3.7) 18 (15.9) 6 (8.1) 0.045
Previous stroke 200 (18.2) 72 (13.1) 45 (17.9) 24 (22.4) 35 (31.0) 24 (32.4) <0.001
Smoking 256 (23.4) 145 (26.4) 58 (23.0) 17 (15.9) 28 (24.8) 8 (10.8) 0.012
Coronary artery disease 209 (19.1) 86 (15.6) 59 (23.4) 20 (18.7) 25 (22.1) 19 (25.7) 0.039
Metabolic syndrome 512 (46.7) 243 (44.2) 124 (49.2) 53 (49.5) 55 (48.7) 37 (50.0) 0.578
Prior medication
Anti-platelet 401 (36.6) 169 (30.7) 99 (39.3) 48 (44.9) 55 (48.7) 30 (40.5) 0.001
Anti-coagulant 62 (5.7) 34 (6.2) 15 (6.0) 2 (1.9) 5 (4.4) 6 (8.1) 0.360
Lipid-lowering agents 213 (19.4) 101 (18.4) 47 (18.7) 23 (21.5) 24 (21.2) 18 (24.3) 0.707
Laboratory findings
Estimate GFR, mL/min/1.73 m2 80.5±27.2 85.8±26.1 78.7±24.4 72.1±29.4 73.2±29.6 70.1±28.1 <0.001
WBC count /103 8.4±3.1 8.5±3.3 8.4±3.0 8.3±3.0 8.1±3.1 7.8±2.0 0.523
Hemoglobin, mg/dL 13.7±1.8 13.8±1.8 13.7±1.8 13.6±1.5 13.4±2.2 13.5±2.0 0.389
Stroke classification 0.618
Large artery atherosclerosis 206 (18.8) 107 (19.5) 42 (16.7) 18 (16.8) 20 (17.7) 19 (25.7)
Lacune 115 (10.5) 52 (9.5) 31 (12.3) 10 (9.3) 11 (9.7) 11 (14.9)
Cardioembolism 285 (26.0) 157 (28.5) 56 (22.2) 27 (25.2) 27 (23.9) 18 (24.3)
Multiple causes 219 (20.0) 106 (19.3) 55 (21.8) 20 (18.7) 26 (23.0) 12 (16.2)
Negative evaluation 271 (24.7) 128 (23.3) 68 (27.0) 32 (29.9) 29 (25.7) 14 (18.9)
Thrombolytic or endovascular 
  reperfusion therapy
113 (10.3) 69 (12.5) 25 (9.9) 7 (6.5) 7 (6.2) 5 (6.8) 0.102
NIHSS score, median (IQR) 3 (1–7) 3 (1-8) 3 (1-7) 3 (1-9) 3 (2-5) 3 (2-6) 0.722
Values are number (%), mean±SD or median (interquartile range).
GFR: glomerular filtration rate, IQR: interquartile range, NIHSS: National Institutes of Health Stroke Scale, SVD: small-vessel disease, WBC: white blood cell.
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Table 2. Comparison of demographic and clinical data according to presence of small vessel pathologies
Cerebral 
microbleeds 
(CMBs)
High grade white 
matter hyperintensities 
(HWHs)
High grade 
perivascular 
spaces (HPVSs)
Asymptomatic 
lacunar infarctions
(ALIs)
CMBs (-)
(n=802)
CMBs (+)
(n=294)
HWHs (-)
(n=916)
HWHs (+)
(n=180)
HPVSs (-)
(n=885)
HPVSs (+)
(n=211)
ALIs (-)
(n=680)
ALIs (+)
(n=416)
Demographic data
Sex, male 495 (61.7) 179 (60.9) 584 (63.8) 90 (50.0)* 547 (61.8) 127 (60.2) 412 (60.6) 262 (63.0)
Age, years 65.0±11.9 69.8±10.9* 64.8±11.8 73.9±8.9* 65.1±11.8 71.0±10.9* 64.8±12.3 68.8±10.6*
Risk factors
Hypertension 568 (70.8) 260 (88.4)* 663 (72.4) 165 (91.7)* 640 (72.3) 188 (89.1)* 469 (69.0) 359 (86.3)*
Diabetes mellitus 239 (29.8) 102 (34.7) 276 (30.1) 65 (36.1) 266 (30.1) 75 (35.5) 198 (29.1) 143 (34.4)
Hyperlipidemia 85 (10.6) 31 (10.5) 99 (10.8) 17 (9.4) 93 (10.5) 23 (10.9) 76 (11.2) 40 (9.6)
Previous stroke 124 (15.5) 76 (25.9)* 147 (16.0) 53 (29.4)* 137 (15.5) 63 (29.9)* 98 (14.4) 102 (24.5)*
Smoking 198 (24.7) 58 (19.7) 234 (25.5) 22 (12.2)* 216 (24.4) 40 (19.0) 168 (24.7) 88 (21.2)
Coronary artery disease 137 (17.1) 72 (24.5)* 170 (18.6) 39 (21.7) 161 (18.2) 48 (22.7) 118 (17.4) 91 (21.9)
Metabolic syndrome 363 (45.3) 149 (50.7) 422 (46.1) 90 (50.0) 412 (46.6) 100 (47.4) 308 (45.3) 204 (49.0)
Prior medication
Antiplatelet 273 (34.0) 128 (43.5)* 317 (34.6) 84 (46.7)* 307 (34.7) 94 (44.5)* 227 (33.4) 174 (41.8)*
Anticoagulant 43 (5.4) 19 (6.5) 54 (5.9) 8 (4.4) 51 (5.8) 11 (5.2) 42 (6.2) 20 (4.8)
Lipid-lowering agents 150 (18.7) 63 (21.4) 175 (19.1) 38 (21.1) 167 (18.9) 46 (21.8) 123 (18.1) 90 (21.6)
Laboratory findings
Estimate GFR, mL/min/1.73 m2 83.9±26.8 71.0±26.0* 82.1±26.0 72.3±31.3* 82.3±26.3 72.9±29.6* 83.3±26.8 75.9±27.2*
WBC count/103 8.4±3.2 8.3±3.0 8.4±3.1 8.2±3.1 8.5±3.3 8.1±2.4 8.6±3.3 8.0±2.8*
Hemoglobin, mg/dL 13.7±1.8 13.6±2.0 13.8±1.8 13.2±1.9 13.7±1.8 13.6±2.0 13.7±1.8 13.7±1.8
Stroke classification
Large artery atherosclerosis 138 (17.2) 68 (23.1) 174 (19.0) 32 (17.8) 159 (18.0) 47 (22.3) 139 (20.4) 67 (16.1)*
Lacune 88 (11.0) 27 (9.2) 93 (10.2) 22 (12.2) 92 (10.4) 23 (10.9) 59 (8.7) 56 (13.5)*
Cardioembolism 210 (26.2) 75 (25.5) 235 (25.7) 50 (27.8) 235 (26.6) 50 (23.7) 197 (29.0) 88 (21.2)*
Multiple causes 165 (20.6) 54 (18.4) 185 (20.2) 34 (18.9) 178 (20.1) 41 (19.4) 127 (18.7) 92 (22.1)*
Negative evaluation 201 (25.1) 70 (23.8) 229 (25.0) 42 (23.3) 221 (25.0) 50 (23.7) 158 (23.2) 113 (27.2)*
Thrombolytic or endovascular 
  reperfusion therapy
83 (10.3) 30 (10.2) 101 (11.0) 12 (6.7) 99 (11.2) 14 (6.6) 89 (13.1) 24 (5.8)*
SVD subtypes
CMBs - - 169 (18.4) 125 (69.4)* 131 (14.8) 163 (77.3)* 100 (14.7) 194 (46.6)*
HWHs 55 (6.9) 125 (42.5)* - - 75 (8.5) 105 (49.8)* 47 (6.9) 133 (32.0)*
HPVSs 48 (6.0) 163 (55.4)* 106 (11.6) 105 (58.3)* - - 41 (6.0) 170 (40.9)*
ALIs 222 (27.7) 194 (66.0)* 283 (30.9) 133 (73.9)* 246 (27.8) 170 (80.6)* - -
NIHSS score, median (IQR) 3 (1–7) 3 (2–6) 3 (1–7) 3 (2–7) 3 (1–7) 4 (2–7) 3 (1–8) 3 (1–5)*
Total SVD score 0.4±0.6 2.6±1.0* 0.6±0.8 3.0±1.0* 0.5±0.7 3.0±0.8* 0.2±0.6 2.1±1.1*
Total SVD score*
0 550 (68.6) 0 (0.0) 550 (60.0) 0 (0.0) 550 (62.1) 0 (0.0) 550 (80.9) 0 (0.0)
1 197 (24.6) 55 (18.7) 232 (25.3) 20 (11.1) 245 (27.7) 7 (3.3) 82 (12.1) 170 (40.9)
2 37 (4.6) 70 (23.8) 76 (8.3) 31 (17.2) 63 (7.1) 44 (20.9) 38 (5.6) 69 (16.6)
3 18 (2.2) 95 (32.3) 58 (6.3) 55 (30.6) 27 (3.1) 86 (40.8) 10 (1.5) 103 (24.8)
4 0 (0.0) 74 (25.2) 0 (0.0) 74 (41.1) 0 (0.0) 74 (35.1) 0 (0.0) 74 (17.8)
Values are number (%), mean±SD or median (IQR). 
*p value<0.05.
GFR: glomerular filtration rate, IQR: interquartile range, NIHSS: National Institutes of Health Stroke Scale, SVD: small-vessel disease, WBC: white blood 
cell.
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no evidence of an interaction between the initial stroke se-
verity and the total CSVD score. Multivariate analysis showed 
that the total CSVD score (as a continuous variable) was 
significantly associated with mortality other than fatal car-
diovascular events during the follow-up in patients with mild 
severe stroke severity but not in those with severe stroke se-
verity at admission (Table 4).
DISCUSSION
Previous studies have proposed using the MRI-based total 
CSVD score for evaluating the total burden of CSVDs,6 but 
no data on the association between this scoring system and 
clinical outcomes during follow-up have been reported pre-
viously. In this study we found that the total CSVD score 
was associated with mortality other than fatal cardiovascular 
events during the follow-up. In addition, a total CSVD score 
of 4 was associated with long-term all-cause mortality as 
well as death from fatal ischemic or hemorrhagic stroke. 
About half of the stroke population had CSVDs in this 
study, with ALIs being most common, followed by CMBs, 
HPVSs, and HWHs. Previous studies have found that many 
patients (up to 60%) with evident stroke or cardiovascular 
diseases had ALIs,18,19 and that ALIs were the most common 
type of CSVD in stroke patients.20 These results were similar 
to our own, although the prevalence of specific CSVDs can 
vary widely depending on the underlying conditions, the im-
aging modality, and the population studied.4,19
Previous studies showed that certain CSVDs such as HWHs, 
CMBs, and ALIs were independent predictors for a poor 
outcome after index stroke21,22 or the long-term fatal out-
come.11,23-25 However, there has been no information on the 
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Fig. 2. Kaplan-Meier survival plots for patients with acute ischemic stroke according to total CSVD score. The Kaplan-Meier curve shows that deaths 
related to all causes (p=0.001) (A), ischemic stroke (p=0.001) (B), and hemorrhagic stroke (p=0.001) (C) were associated with the total CSVD score, 
whereas fatal cardiovascular events were not (p=0.100) (D). CSVD: cerebral small-vessel disease, SVD: small-vessel disease.
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impact of the total burden of CSVDs on clinical outcomes 
despite various types of CSVDs commonly coexisting and 
the clinical outcome possibly being determined by their 
combined effect. Considering the potential impact of the 
underlying total burden of CSVD on cognitive decline and 
physical disability,13 patients with a higher total CSVD score 
might remain undertreated with rehabilitation or medica-
tion for secondary stroke prevention. In addition, severe 
CSVD could be a marker of an impaired neurovascular net-
work, which could inhibit plasticity and adversely affect the 
recovery after stroke.26 A high CSVD burden has also been 
associated with other neurodegenerative diseases13 that have 
a detrimental effect on the outcome after stroke. Along with 
these previous reports, our results showed that the total 
burden of CSVD can affect the outcomes after index stroke. 
In should be noted that in an acute stroke population such 
as the present one, the potential impact of the CSVD bur-
den on clinical outcome could be attenuated due to the pres-
ence of other stronger factors affecting the outcomes, such 
as the initial stroke severity.10,23 We found that an impact of 
the total CSVD burden was not present in patients who had 
severe stroke. This means that the impact of the CSVD bur-
Table 3. Multivariable Cox regression analysis for long-term mortality according to presence and burden of SVD
Cause of death
All-cause† Fatal cardiovascular events‡ Ischemic stroke§ Hemorrhagic stroke∥
Presence of SVD
Cerebral microbleeds 1.33 (1.00–1.76)* 1.61 (0.59–4.41) 1.23 (0.74–2.06) 10.15 (2.10–48.89)*
High grade white matter hyperintensities 1.56 (1.16–2.11)* 1.61 (0.55–4.65) 2.40 (1.44–4.01)* 7.42 (1.99–27.66)*
High grade perivascular spaces 1.83 (1.38–2.44)* 1.11 (0.37–3.33) 2.02 (1.24–3.29)* 5.29 (1.58–22.06)*
Asymptomatic lacunar infarctions 1.16 (0.89–1.52) 1.37 (0.48–3.87) 0.89 (0.55–1.44) 2.03 (0.54–7.56)
Total SVD score, per 1 point 1.18 (1.07–1.30)* 1.17 (0.82–1.67) 1.20 (1.01–1.42)* 2.05 (1.30–3.22)*
Total SVD score
0 1 1 1 1
1 1.17 (0.83–1.66) 2.88 (0.76–10.92) 1.31 (0.70–2.43) 1.10 (0.10–12.18)
2 1.42 (0.93–2.16) 0.76 (0.08–7.19) 1.20 (0.57–2.53) 2.81 (0.25–30.99)
3 1.44 (0.94–2.21) 3.37 (0.77–14.73) 1.07 (0.45–2.54) 2.55 (0.23–28.13)
4 2.11 (1.36–3.25)* 1.92 (0.31–11.79) 2.74 (1.34–5.60)* 17.44 (3.19–95.39)*
Values are hazard ratio (95% confidence interval).  
*p value<0.05, †Adjusted for age, sex, and variables with p value<0.1 in univariate analysis (hyperlipidemia, previous stroke, smoking, coronary artery 
disease, metabolic syndrome, prior anti-coagulant use, white blood cell count, hemoglobin, stroke classification, thrombolytic or endovascular reper-
fusion therapy, and NIHSS score) for all-cause mortality, ‡Adjusted for age, sex, and variables with p value<0.1 in univariate analysis (coronary artery 
disease, previous antiplatelet medication, estimated glomerular filtration rate, hemoglobin, and NIHSS score) for fatal cardiovascular events, §Adjusted 
for age, sex, and variables with p value<0.1 in univariate analysis (previous stroke, smoking, metabolic syndrome, prior anti-coagulant use, white 
blood cell count, hemoglobin, stroke classification, thrombolytic or endovascular reperfusion therapy, and NIHSS score) for ischemic stroke mortality, 
∥Adjusted each component of SVD and total SVD score only for hemorrhagic stroke mortality.
NIHSS: National Institutes of Health Stroke Scale, SVD: small-vessel disease.
Table 4. Multivariate analysis of SVD score for outcome according to the stroke severity
Outcomes
NIHSS score
0–4 (n=708) 5–15 (n=298) >15 (n=90)
All-cause mortality 1.29 (1.12–1.50)* 1.11 (0.93–1.33) 0.93 (0.68–1.29)
Fatal cardiovascular events 1.13 (0.59–2.15) 1.00 (0.52–1.91) 0.57 (0.10–3.16)
Fatal ischemic stroke 1.69 (1.19–2.40)* 1.03 (0.75–1.40) 0.63 (0.39–1.16)
Fatal hemorrhagic stroke 2.00 (1.19–3.35)* NA 1.36 (0.29–6.37)
Values are hazard ratio (95% confidence interval). All results are represented as adjusted hazard ratio according to total SVD score (per 1 point). There 
was no evidence of interaction between initial stroke severity and total SVD score. Adjusted for age, sex, and variables with p value<0.1 in univariate 
analysis (hyperlipidemia, previous stroke, smoking, coronary artery disease, metabolic syndrome, prior anti-coagulant use, white blood cell count, he-
moglobin, stroke classification, thrombolytic or endovascular reperfusion therapy, and NIHSS score) for all-cause mortality. Adjusted for age, sex, and 
variables with p value<0.1 in univariate analysis (coronary artery disease, prior antiplatelet medication, estimated glomerular filtration rate, hemoglo-
bin, and NIHSS score) for fatal cardiovascular events. Adjusted for age, sex, and variables with p value<0.1 in univariate analysis (previous stroke, 
smoking, metabolic syndrome, prior anti-coagulant use, white blood cell count, hemoglobin, stroke classification, thrombolytic or endovascular reper-
fusion therapy, and NIHSS score) for ischemic stroke mortality. Adjusted each component of SVD and total SVD score only for hemorrhagic stroke 
mortality.
*p value<0.05.
NA: not applicable, NIHSS: National Institutes of Health Stroke Scale, SVD: small-vessel disease.
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den on outcome can differ with the patient’s characteristics, 
including age and the severity of the index stroke.
The mortality rate in this study was higher than in previ-
ous studies.27-31 Stroke outcomes (including mortality) can 
vary with the patient’s characteristics, stroke subtype, and 
acute stroke care. Our study population had a higher age and 
higher proportion of the cardioembolic or multiple-causes 
stroke subtype compared to other previous studies,30,31 which 
may have affected the present results.
This study was subject to some limitations. First, it had a 
retrospective design, which is a substantial weak point of 
this type of study. Second, we did not investigate stroke re-
currence, and so it was uncertain whether the higher mortal-
ity rate in patients with a higher burden of CSVDs was due 
to increased stroke recurrence. Third, the degree of adher-
ence to medication used for stroke prevention, which is an-
other factor affecting recurrent ischemic or hemorrhagic 
stroke, was not investigated during the follow-up. Fourth, 
we did not exclude patients with previous disability before 
index stroke. Fifth, we cannot guarantee that each CSVD 
subtype, particularly ALIs, was truly asymptomatic, although 
we did determine the presence of previous stroke based on 
patient recall. A neurologic deficit that is not recognized as 
being due to a previous stroke might affect the clinical stroke 
outcome.32 Sixth, the smallness of the sample for hemor-
rhagic stroke mortality means that the associated data should 
be interpreted with caution. Lastly, our study population in-
cluded only Asian (Korean) patients. This homogeneity of 
the study population should be considered when interpret-
ing our results because the association between CSVD and 
clinical outcome could differ with ethnicity.33
In conclusion, this study has shed light on the association 
of the total CSVD score with mortality during follow-up in 
acute ischemic stroke patients. The different types of CSVD 
frequently coexist, and the simple scoring system that com-
bines the various types of CSVD in a single scale is easy to 
use. Our findings suggest that this scoring system could be 
useful for risk stratification in future clinical research.
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